Key facts
- It has raised $50.8M; the latest was Later Stage VC ($6.8M) in Aug 2025.
- Notable investors include Keiretsu Forum, Innosuisse, Ligo Partners, Side Door Ventures, Globivest — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Orion Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Orion Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orion Biotechnology
Operator of a clinical-stage biotechnology company, intended to develop novel medical treatments and therapies for the prevention and treatment of global health issues. The company specializes in developing biological therapeutics based on Chemokine Analogue inhibitors and other G-Protein Coupled Receptors, for the treatment of a broad range of serious unmet medical needs, enabling healthcare professionals to develop analogs with superior binding affinity, potency, and pharmacological control.
- Sector
- Healthcare
- HQ
- Ottawa, Canada
- Founded
- 2017
- Employees
- 20
- Website
- orionbiotechnology.com/
- Ownership
- Privately Held (backing)
Orion Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orion Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orion Biotechnology in its N-PORT filings yet. We sweep new filings monthly.